KIF22 in the Prognosis and Immune Biomarking of Pan-Cancer
KIF22, also known as kinesin-like DNA-binding protein (Kid), is a member of the Kinesin superfamily proteins (KIFs). Available evidence indicated that KIF22 was associated with cancer occurrence and development. However, the functions and underlying mechanisms of KIF22 in carcinogenesis and cancer p...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2023/9542311 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306925671383040 |
|---|---|
| author | Xiuhong Guo Huayue Cao Mei Hu Yuening Wu Jingxiang Li |
| author_facet | Xiuhong Guo Huayue Cao Mei Hu Yuening Wu Jingxiang Li |
| author_sort | Xiuhong Guo |
| collection | DOAJ |
| description | KIF22, also known as kinesin-like DNA-binding protein (Kid), is a member of the Kinesin superfamily proteins (KIFs). Available evidence indicated that KIF22 was associated with cancer occurrence and development. However, the functions and underlying mechanisms of KIF22 in carcinogenesis and cancer progression remain largely unknown. In this study, we examined the expression profile and methylation status of KIF22 in different cancers, as well as its associations with prognosis, tumor stemness, genomic heterogeneity, immune evasion, immune infiltration, and therapeutic response in various tumor types. The results demonstrated that the expression level of KIF22 was higher in tumors than nontumor tissues and had strong relationships with prognosis, genomic heterogeneity, tumor stemness, neoantigen, ESTIMATE, and immune infiltration. KIF22 methylation status showed strong relationships with immunomodulators and chemokines. KIF22 had a significant relevance with drug susceptibility and could be a useful biomarker for forecasting survival probability and therapeutic reaction. Furthermore, KIF22 interaction and coexpression networks were mainly involved in cell division, cell cycle, DNA repair, and antigen processing and presentation. KIF22 could be used as a pan-cancer biomarker for clinical diagnosis, therapeutic schedule, prognosis, and cancer monitoring. |
| format | Article |
| id | doaj-art-24a87e8a6f3f40a9bab3e9fbdec31138 |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-24a87e8a6f3f40a9bab3e9fbdec311382025-08-20T03:54:56ZengWileyJournal of Immunology Research2314-71562023-01-01202310.1155/2023/9542311KIF22 in the Prognosis and Immune Biomarking of Pan-CancerXiuhong Guo0Huayue Cao1Mei Hu2Yuening Wu3Jingxiang Li4Oral & Maxillofacial Reconstruction and Regeneration of Luzhou Key LaboratoryDepartment of Oral ImplantologyDepartment of UltrasoundOral & Maxillofacial Reconstruction and Regeneration of Luzhou Key LaboratoryOral & Maxillofacial Reconstruction and Regeneration of Luzhou Key LaboratoryKIF22, also known as kinesin-like DNA-binding protein (Kid), is a member of the Kinesin superfamily proteins (KIFs). Available evidence indicated that KIF22 was associated with cancer occurrence and development. However, the functions and underlying mechanisms of KIF22 in carcinogenesis and cancer progression remain largely unknown. In this study, we examined the expression profile and methylation status of KIF22 in different cancers, as well as its associations with prognosis, tumor stemness, genomic heterogeneity, immune evasion, immune infiltration, and therapeutic response in various tumor types. The results demonstrated that the expression level of KIF22 was higher in tumors than nontumor tissues and had strong relationships with prognosis, genomic heterogeneity, tumor stemness, neoantigen, ESTIMATE, and immune infiltration. KIF22 methylation status showed strong relationships with immunomodulators and chemokines. KIF22 had a significant relevance with drug susceptibility and could be a useful biomarker for forecasting survival probability and therapeutic reaction. Furthermore, KIF22 interaction and coexpression networks were mainly involved in cell division, cell cycle, DNA repair, and antigen processing and presentation. KIF22 could be used as a pan-cancer biomarker for clinical diagnosis, therapeutic schedule, prognosis, and cancer monitoring.http://dx.doi.org/10.1155/2023/9542311 |
| spellingShingle | Xiuhong Guo Huayue Cao Mei Hu Yuening Wu Jingxiang Li KIF22 in the Prognosis and Immune Biomarking of Pan-Cancer Journal of Immunology Research |
| title | KIF22 in the Prognosis and Immune Biomarking of Pan-Cancer |
| title_full | KIF22 in the Prognosis and Immune Biomarking of Pan-Cancer |
| title_fullStr | KIF22 in the Prognosis and Immune Biomarking of Pan-Cancer |
| title_full_unstemmed | KIF22 in the Prognosis and Immune Biomarking of Pan-Cancer |
| title_short | KIF22 in the Prognosis and Immune Biomarking of Pan-Cancer |
| title_sort | kif22 in the prognosis and immune biomarking of pan cancer |
| url | http://dx.doi.org/10.1155/2023/9542311 |
| work_keys_str_mv | AT xiuhongguo kif22intheprognosisandimmunebiomarkingofpancancer AT huayuecao kif22intheprognosisandimmunebiomarkingofpancancer AT meihu kif22intheprognosisandimmunebiomarkingofpancancer AT yueningwu kif22intheprognosisandimmunebiomarkingofpancancer AT jingxiangli kif22intheprognosisandimmunebiomarkingofpancancer |